830 related articles for article (PubMed ID: 28695552)
21. Prescription of lipid-lowering medications for patients with type 2 diabetes mellitus and risk-associated LDL cholesterol: a nationwide study of guideline adherence from the Swedish National Diabetes Register.
Karlsson SA; Franzén S; Svensson AM; Miftaraj M; Eliasson B; Andersson Sundell K
BMC Health Serv Res; 2018 Nov; 18(1):900. PubMed ID: 30486824
[TBL] [Abstract][Full Text] [Related]
22. Metabolic control and cardiovascular risk factors in type 2 diabetes mellitus patients according to diabetes duration.
Franch-Nadal J; Roura-Olmeda P; Benito-Badorrey B; Rodriguez-Poncelas A; Coll-de-Tuero G; Mata-Cases M;
Fam Pract; 2015 Feb; 32(1):27-34. PubMed ID: 25194144
[TBL] [Abstract][Full Text] [Related]
23. Potential implications of the choice among three alternative treatment targets for apolipoprotein B100 in the management of patients with type 2 diabetes and chronic kidney disease.
Boronat M; García-Cantón C; López-Ríos L; Quevedo V; Lorenzo DL; Batista F; Riaño M; Nóvoa FJ
Diab Vasc Dis Res; 2014 Jan; 11(1):53-9. PubMed ID: 24254975
[TBL] [Abstract][Full Text] [Related]
24. Factors associated with therapeutic goal attainment in patients with concomitant hypertension and dyslipidemia.
Chopra I; Kamal KM
Hosp Pract (1995); 2014 Apr; 42(2):77-88. PubMed ID: 24769787
[TBL] [Abstract][Full Text] [Related]
25. [Therapeutic approach to dyslipidemia and goal achievement in a Spanish population with type 2 diabetes without cardiovascular disease].
Pérez A; González Blanco C; Hernández-Presa MÁ; Chaves J
Endocrinol Nutr; 2011; 58(6):283-90. PubMed ID: 21641286
[TBL] [Abstract][Full Text] [Related]
26. Factors Associated With Achievement of Blood Pressure, Low-Density Lipoprotein Cholesterol (LDL-C), and Glycemic Targets for Primary Prevention of Cardiovascular Diseases Among High Cardiovascular Risk Malaysians in Primary Care.
Baharudin N; Ramli AS; Ramland SS; Badlie-Hisham NI; Mohamed-Yassin MS
J Prim Care Community Health; 2023; 14():21501319231191017. PubMed ID: 37551146
[TBL] [Abstract][Full Text] [Related]
27. Effect of glycemic and lipid achievements on clinical outcomes type 2 diabetic, Chinese patients with stable coronary artery disease.
Li S; Zhang Y; Guo YL; Zhu CG; Wu NQ; Qing P; Gao Y; Sun J; Liu G; Dong Q; Li JJ
J Diabetes Complications; 2016; 30(1):115-20. PubMed ID: 26481154
[TBL] [Abstract][Full Text] [Related]
28. Current cardiovascular risk management patterns with special focus on lipid lowering in daily practice in Switzerland.
Jaussi A; Noll G; Meier B; Darioli R
Eur J Cardiovasc Prev Rehabil; 2010 Jun; 17(3):363-72. PubMed ID: 20168234
[TBL] [Abstract][Full Text] [Related]
29. Comparison of primary versus secondary prevention of cardiovascular disease in patients with type2 diabetes: Focus on achievement of ABC goals.
Rabizadeh S; Mansournia MA; Salehi SS; Khaloo P; Alemi H; Mirbolouk H; Blaha MJ; Esteghamati A; Nakhjavani M
Diabetes Metab Syndr; 2019; 13(3):1733-1737. PubMed ID: 31235086
[TBL] [Abstract][Full Text] [Related]
30. Primary Prevention of Cardiovascular Risk in Lithuania-Results from EUROASPIRE V Survey.
Urbonas G; Vencevičienė L; Valius L; Krivickienė I; Petrauskas L; Lazarenkienė G; Karpavičienė J; Briedė G; Žučenkienė E; Vencevičius K
Medicina (Kaunas); 2020 Mar; 56(3):. PubMed ID: 32197516
[No Abstract] [Full Text] [Related]
31. Non-HDL cholesterol goal attainment and its relationship with triglyceride concentrations among diabetic subjects with cardiovascular disease: A nationwide survey of 2674 individuals in Hungary.
Mark L; Vallejo-Vaz AJ; Reiber I; Paragh G; Kondapally Seshasai SR; Ray KK
Atherosclerosis; 2015 Jul; 241(1):62-8. PubMed ID: 25966441
[TBL] [Abstract][Full Text] [Related]
32. Primacy of the 3B approach to control risk factors for cardiovascular disease in type 2 diabetes patients.
Ji L; Hu D; Pan C; Weng J; Huo Y; Ma C; Mu Y; Hao C; Ji Q; Ran X; Su B; Zhuo H; Fox KA; Weber M; Zhang D; ;
Am J Med; 2013 Oct; 126(10):925.e11-22. PubMed ID: 23810406
[TBL] [Abstract][Full Text] [Related]
33. Efficacy of intensive multitherapy for patients with type 2 diabetes mellitus: a randomized controlled trial.
Ménard J; Payette H; Baillargeon JP; Maheux P; Lepage S; Tessier D; Ardilouze JL
CMAJ; 2005 Dec; 173(12):1457-66. PubMed ID: 16293781
[TBL] [Abstract][Full Text] [Related]
34. The evaluation of low-density lipoprotein cholesterol goals achieved in patients with established cardiovascular disease and/or hyperlipidaemia receiving lipid-lowering therapy: the South African Not at Goal study (SA-NAG).
Ramjeeth A; Butkow N; Raal FJ; Maholwana-Mokgatlhe M
Cardiovasc J Afr; 2008; 19(2):88-94. PubMed ID: 18516354
[TBL] [Abstract][Full Text] [Related]
35. The impact of serum lipids on risk for microangiopathy in patients with type 2 diabetes mellitus.
Toth PP; Simko RJ; Palli SR; Koselleck D; Quimbo RA; Cziraky MJ
Cardiovasc Diabetol; 2012 Sep; 11():109. PubMed ID: 22978715
[TBL] [Abstract][Full Text] [Related]
36. Variability in HbA1c, blood pressure, lipid parameters and serum uric acid, and risk of development of chronic kidney disease in type 2 diabetes.
Ceriello A; De Cosmo S; Rossi MC; Lucisano G; Genovese S; Pontremoli R; Fioretto P; Giorda C; Pacilli A; Viazzi F; Russo G; Nicolucci A;
Diabetes Obes Metab; 2017 Nov; 19(11):1570-1578. PubMed ID: 28432733
[TBL] [Abstract][Full Text] [Related]
37. ["Diabetes in Germany"(DIG) study. A prospective 4-year-follow-up study on the quality of treatment for type 2 diabetes in daily practice].
Ott P; Benke I; Stelzer J; Köhler C; Hanefeld M
Dtsch Med Wochenschr; 2009 Feb; 134(7):291-7. PubMed ID: 19197810
[TBL] [Abstract][Full Text] [Related]
38. Blood pressure and low-density lipoprotein cholesterol control status in Chinese hypertensive dyslipidemia patients during lipid-lowering therapy.
Yan X; Li Y; Dong Y; Wu Y; Li J; Bian R; Hu D
Lipids Health Dis; 2019 Jan; 18(1):32. PubMed ID: 30696435
[TBL] [Abstract][Full Text] [Related]
39. Type 1 diabetes management: Room for improvement.
Varkevisser RDM; Birnie E; Mul D; van Dijk PR; Aanstoot HJ; Wolffenbuttel BHR; van der Klauw MM
J Diabetes; 2023 Mar; 15(3):255-263. PubMed ID: 36808864
[TBL] [Abstract][Full Text] [Related]
40. Cardiovascular risk factors and metabolic control in type 2 diabetic subjects attending outpatient clinics in Italy: the SFIDA (survey of risk factors in Italian diabetic subjects by AMD) study.
Comaschi M; Coscelli C; Cucinotta D; Malini P; Manzato E; Nicolucci A;
Nutr Metab Cardiovasc Dis; 2005 Jun; 15(3):204-11. PubMed ID: 15955469
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
